Loading...
•
Jun 30, 2022
Novavax Q2 2022 Earnings Report
Announced financial results and operational highlights for the second quarter ended June 30, 2022.
Key Takeaways
Novavax reported its Q2 2022 financial results, highlighting the delivery of its vaccine to the U.S. market and global distribution with over 23 million doses delivered since the start of Q3.
Delivered vaccine to the U.S. market with immunizations underway.
Distributed over 23 million doses globally since the start of the third quarter.
Gained positive momentum moving into the remainder of 2022 and into 2023.
Confident that the vaccine will play an important role in the long-term COVID-19 landscape through continued expansions to the label for adolescents and boosting and the vaccine’s competitive product profile.
Forward Guidance
Novavax is revising full year 2022 total revenue guidance to $2 to $2.3 billion. Total revenue reflects all sources, including product sales of Nuvaxovid by Novavax, grants revenue, royalties and other revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...